REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Study sponsor: Sutro Biopharma, Inc. · STRO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-08-26Actual
Enrollment · participants600Actual
Source updated2025-09-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.